These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 11218998)

  • 21. Nevirapine in children.
    Proj Inf Perspect; 1998 Dec; (26):7. PubMed ID: 11366500
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hyperlactatemia due to nevirapine.
    Panos G; Kopterides P; Falagas ME
    Ann Intern Med; 2006 Dec; 145(11):867-8. PubMed ID: 17146078
    [No Abstract]   [Full Text] [Related]  

  • 23. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
    Arranz Caso JA; López JC; Santos I; Estrada V; Castilla V; Sanz J; Sanz J; Molina JP; Fernández Guerrero M; Górgolas M
    HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nevirapine-induced hepatitis treated with corticosteroids?
    Leitze Z; Nadeem A; Choudhary A; Saul Z; Roberts I; Manthous CA
    AIDS; 1998 Jun; 12(9):1115-7. PubMed ID: 9662216
    [No Abstract]   [Full Text] [Related]  

  • 25. Plasma exchange; a promising treatment for toxic epidermal necrolysis with AIDS.
    Nomura T; Abe R; Fujimoto K; Endo T; Shimizu H; Koike T
    AIDS; 2004 Dec; 18(18):2446-8. PubMed ID: 15622328
    [No Abstract]   [Full Text] [Related]  

  • 26. Spanish study looks at the effect of nevirapine on the liver.
    TreatmentUpdate; 2001 Jul; 13(3):4-5. PubMed ID: 11569988
    [No Abstract]   [Full Text] [Related]  

  • 27. Symptomatic hyperlactatemia associated with nucleoside analogue reverse-transcriptase inhibitor use in HIV-infected patients: a report of 24 cases in a resource-limited setting (Uganda).
    Songa PM; Castelnuovo B; Mugasha EB; Ocama P; Kambugu A
    Clin Infect Dis; 2007 Aug; 45(4):514-7. PubMed ID: 17638205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gender difference in Nevirapine-associated rash.
    Proj Inf Perspect; 1999 Apr; (27):11. PubMed ID: 11366728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is nevirapine-based therapy discontinuation in hepatitis C co-infected patients a more important mortality determinant than hypersensitivity.
    Raffi F; Lewden C; Chêne G
    AIDS; 2008 Jan; 22(3):435-6. PubMed ID: 18195573
    [No Abstract]   [Full Text] [Related]  

  • 30. Nevirapine-induced neuropsychiatric complications, a class effect of non-nucleoside reverse transcriptase inhibitors?
    Morlese JF; Qazi NA; Gazzard BG; Nelson MR
    AIDS; 2002 Sep; 16(13):1840-1. PubMed ID: 12218402
    [No Abstract]   [Full Text] [Related]  

  • 31. [Hepatitis and nevirapine].
    Palacios R; Santos J; González M; Márquez M
    Med Clin (Barc); 2000 Apr; 114(15):597-8. PubMed ID: 10846681
    [No Abstract]   [Full Text] [Related]  

  • 32. Labeling changes for Viramune.
    AIDS Patient Care STDS; 2008 Jul; 22(7):604-5. PubMed ID: 18661593
    [No Abstract]   [Full Text] [Related]  

  • 33. [Stevens-Johnson syndrome due to nevirapine].
    García Fernández D; García-Patos Briones V; Mollet Sánchez J; Castells Rodellas A
    Rev Clin Esp; 2000 Mar; 200(3):179-80. PubMed ID: 10804771
    [No Abstract]   [Full Text] [Related]  

  • 34. Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up.
    Negredo E; Paredes R; Bonjoch A; Tuldrà A; Fumaz CR; Gel S; Garcés B; Johnston S; Arnó A; Balagué M; Jou A; Tural C; Sirera G; Romeu J; Cruz L; Francia E; Domingo P; Arrizabalaga J; Ruiz I; Arribas JR; Ruiz L; Clotet B
    Antivir Ther; 1999; 4 Suppl 3():23-8. PubMed ID: 16021868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1.
    Krogstad P; Lee S; Johnson G; Stanley K; McNamara J; Moye J; Jackson JB; Aguayo R; Dieudonne A; Khoury M; Mendez H; Nachman S; Wiznia A;
    Clin Infect Dis; 2002 Apr; 34(7):991-1001. PubMed ID: 11880966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nevirapine-induced Stevens-Johnson syndrome in a mother and son.
    Liechty CA; Solberg P; Mwima G; Were W; Weidle PJ; Mermin J
    AIDS; 2005 Jun; 19(9):993-4. PubMed ID: 15905686
    [No Abstract]   [Full Text] [Related]  

  • 37. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).
    Negredo E; Miró O; Rodríguez-Santiago B; Garrabou G; Estany C; Masabeu A; Force L; Barrufet P; Cucurull J; Domingo P; Alonso-Villaverde C; Bonjoch A; Morén C; Pérez-Alvarez N; Clotet B;
    Clin Infect Dis; 2009 Sep; 49(6):892-900. PubMed ID: 19663689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV drug nevirapine (Viramune): risk of severe hepatotoxicity.
    Wooltorton E
    CMAJ; 2004 Mar; 170(7):1091. PubMed ID: 15051689
    [No Abstract]   [Full Text] [Related]  

  • 39. Widespread vitiligo after erythroderma caused by nevirapine in a patient with AIDS.
    Ramírez-Hernández M; Sánchez-Sierra B; Martínez-Escribano JA
    Acta Derm Venereol; 2007; 87(5):442-3. PubMed ID: 17721659
    [No Abstract]   [Full Text] [Related]  

  • 40. Diffuse interstitial pulmonary opacities induced by nevirapine.
    Sankatsing SU; Schouten WE
    AIDS; 2007 Sep; 21(14):1993-4. PubMed ID: 17721119
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.